Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of teduglutide in Japanese subjects with short bowel syndrome
jRCT2080223972Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Started Jul 2018; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on jRCT2080223972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223972.